← All trials
NCT05773586
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Mar 15, 2026
- First posted
- Mar 17, 2023
- Last posted
- Nov 8, 2023
- Enrollment
- 105
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Southern Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.